{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T01:57:13Z","timestamp":1775786233983,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T00:00:00Z","timestamp":1618790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T00:00:00Z","timestamp":1618790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"National Institute of Health","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1245\/s10434-021-09910-2","type":"journal-article","created":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T18:38:42Z","timestamp":1618857522000},"page":"6044-6050","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Is Residual Nodal Disease at Axillary Dissection Associated with Tumor Subtype in Patients with Low Volume Sentinel Node Metastasis After Neoadjuvant Chemotherapy?"],"prefix":"10.1245","volume":"28","author":[{"given":"Tracy-Ann","family":"Moo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate R.","family":"Pawloski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcia","family":"Edelweiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiana","family":"Le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audree","family":"Tadros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea V.","family":"Barrio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,19]]},"reference":[{"issue":"6","key":"9910_CR1","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1245\/s10434-018-6429-2","volume":"25","author":"TA Moo","year":"2018","unstructured":"Moo TA, Edelweiss M, Hajiyeva S, et al. Is low-volume disease in the sentinel node after neoadjuvant chemotherapy an indication for axillary dissection? Ann Surg Oncol. 2018;25(6):1488\u201394.","journal-title":"Ann Surg Oncol."},{"issue":"10","key":"9910_CR2","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1245\/s10434-018-6578-3","volume":"25","author":"AU Barron","year":"2018","unstructured":"Barron AU, Hoskin TL, Boughey JC. Predicting non-sentinel lymph node metastases in patients with a positive sentinel lymph node after neoadjuvant chemotherapy. Ann Surg Oncol. 2018;25(10):2867\u201374.","journal-title":"Ann Surg Oncol."},{"issue":"18","key":"9910_CR3","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1016\/j.ejca.2012.05.023","volume":"48","author":"N Houssami","year":"2012","unstructured":"Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer. 2012;48(18):3342\u201354.","journal-title":"Eur J Cancer."},{"issue":"9","key":"9910_CR4","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1245\/s10434-018-6637-9","volume":"25","author":"TT Nguyen","year":"2018","unstructured":"Nguyen TT, Hoskin TL, Day CN, et al. Decreasing use of axillary dissection in node-positive breast cancer patients treated with neoadjuvant chemotherapy. Ann Surg Oncol. 2018;25(9):2596\u2013602.","journal-title":"Ann Surg Oncol."},{"issue":"11","key":"9910_CR5","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1245\/s10434-016-5246-8","volume":"23","author":"A Mamtani","year":"2016","unstructured":"Mamtani A, Barrio AV, King TA, et al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study. Ann Surg Oncol. 2016;23(11):3467\u201374.","journal-title":"Ann Surg Oncol."},{"issue":"12","key":"9910_CR6","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1001\/jamasurg.2018.2696","volume":"153","author":"AU Barron","year":"2018","unstructured":"Barron AU, Hoskin TL, Day CN, Hwang ES, Kuerer HM, Boughey JC. Association of low nodal positivity rate among patients with ERBB2-positive or triple-negative breast cancer and breast pathologic complete response to neoadjuvant chemotherapy. JAMA Surg. 2018;153(12):1120\u20136.","journal-title":"JAMA Surg."},{"key":"9910_CR7","doi-asserted-by":"crossref","unstructured":"Montagna G, Mamtani A, Knezevic A, Brogi E, Barrio AV, Morrow M. Selecting node-positive patients for axillary downstaging with neoadjuvant chemotherapy. Ann Surg Oncol. 2020;27:4515\u201322.","DOI":"10.1245\/s10434-020-08650-z"},{"key":"9910_CR8","doi-asserted-by":"crossref","unstructured":"Piltin MA, Hoskin TL, Day CN, Davis J Jr, Boughey JC. Oncologic outcomes of sentinel lymph node surgery after neoadjuvant chemotherapy for node-positive breast cancer. Ann Surg Oncol. 2020;27:4795\u20134801.","DOI":"10.1245\/s10434-020-08900-0"},{"issue":"7","key":"9910_CR9","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617\u201328.","journal-title":"N Engl J Med."},{"issue":"22","key":"9910_CR10","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147\u201359.","journal-title":"N Engl J Med."},{"key":"9910_CR11","unstructured":"American Joint Committee on Cancer. AJCC cancer staging manual breast cancer, 7th edition. Published 2009. Accessed November, 2018."},{"issue":"11","key":"9910_CR12","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1245\/s10434-019-07583-6","volume":"26","author":"SM Wong","year":"2019","unstructured":"Wong SM, Weiss A, Mittendorf EA, King TA, Golshan M. Surgical management of the axilla in clinically node-positive patients receiving neoadjuvant chemotherapy: a National Cancer Database analysis. Ann Surg Oncol. 2019;26(11):3517\u201325.","journal-title":"Ann Surg Oncol."},{"issue":"10","key":"9910_CR13","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1245\/s10434-017-5958-4","volume":"24","author":"AS Caudle","year":"2017","unstructured":"Caudle AS, Bedrosian I, Milton DR, et al. Use of sentinel lymph node dissection after neoadjuvant chemotherapy in patients with node-positive breast cancer at diagnosis: practice patterns of American Society of Breast Surgeons members. Ann Surg Oncol. 2017;24(10):2925\u201334.","journal-title":"Ann Surg Oncol."},{"issue":"10","key":"9910_CR14","doi-asserted-by":"publisher","first-page":"3305","DOI":"10.1245\/s10434-019-07540-3","volume":"26","author":"MK Srour","year":"2019","unstructured":"Srour MK, Tseng J, Luu M, Alban RF, Giuliano AE, Chung A. Patterns in the use of axillary operations for patients with node-positive breast cancer after neoadjuvant chemotherapy: a National Cancer Database (NCDB) analysis. Ann Surg Oncol. 2019;26(10):3305\u201311.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"9910_CR15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.clbc.2015.09.003","volume":"16","author":"I van den Hoven","year":"2016","unstructured":"van den Hoven I, van Klaveren D, Voogd AC, Vergouwe Y, Tjan-Heijnen V, Roumen RM. A Dutch prediction tool to assess the risk of additional axillary non-sentinel lymph node involvement in sentinel node-positive breast cancer patients. Clin Breast Cancer. 2016;16(2):123\u201330.","journal-title":"Clin Breast Cancer."},{"issue":"4","key":"9910_CR16","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.amjsurg.2005.06.008","volume":"190","author":"AC Degnim","year":"2005","unstructured":"Degnim AC, Reynolds C, Pantvaidya G, et al. Nonsentinel node metastasis in breast cancer patients: assessment of an existing and a new predictive nomogram. Am J Surg. 2005;190(4):543\u201350.","journal-title":"Am J Surg."},{"issue":"10","key":"9910_CR17","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1245\/ASO.2003.03.015","volume":"10","author":"KJ Van Zee","year":"2003","unstructured":"Van Zee KJ, Manasseh DM, Bevilacqua JL, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol. 2003;10(10):1140\u201351.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"9910_CR18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/SLA.0b013e318238f461","volume":"255","author":"EA Mittendorf","year":"2012","unstructured":"Mittendorf EA, Hunt KK, Boughey JC, et al. Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. Ann Surg. 2012;255(1):109\u201315.","journal-title":"Ann Surg."},{"issue":"4","key":"9910_CR19","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1470-2045(13)70035-4","volume":"14","author":"V Galimberti","year":"2013","unstructured":"Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23\u201301): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14(4):297\u2013305.","journal-title":"Lancet Oncol."},{"issue":"5","key":"9910_CR20","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1097\/SLA.0000000000002313","volume":"267","author":"HM Kuerer","year":"2018","unstructured":"Kuerer HM, Rauch GM, Krishnamurthy S, et al. A clinical feasibility trial for Iidentification of exceptional responders in whom breast cancer surgery can be eliminated following neoadjuvant systemic therapy. Ann Surg. 2018;267(5):946\u201351.","journal-title":"Ann Surg."},{"issue":"6","key":"9910_CR21","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1159\/000489565","volume":"13","author":"C Liedtke","year":"2018","unstructured":"Liedtke C, G\u00f6rlich D, Bauerfeind I, et al. Validation of a nomogram predicting non-sentinel lymph node metastases among patients with breast cancer after primary systemic therapy - a transSENTINA substudy. Breast Care (Basel). 2018;13(6):440\u20136.","journal-title":"Breast Care (Basel)."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-09910-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-021-09910-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-09910-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T01:09:43Z","timestamp":1632445783000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-021-09910-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,19]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["9910"],"URL":"https:\/\/doi.org\/10.1245\/s10434-021-09910-2","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,19]]},"assertion":[{"value":"23 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Monica Morrow reports honoraria from Genomic Health and Roche. No other disclosures were reported.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}